Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 5, 2008, Pages 1794-1798

  Goldwater, D Ronald ^a   Dougherty, Carolyn ^b   Schumacher, Mary ^b   Villano, Stephen A ^b  

^a PAREXEL INTERNATIONAL   (United States)

^b ViroPharma Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAVIR; BILIRUBIN; CYTOCHROME P450 3A4; DRUG METABOLITE; HEMOGLOBIN; KETOCONAZOLE; VP 44469;

ABDOMINAL PAIN; ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; ENZYME ACTIVITY; ENZYME INHIBITION; EOSINOPHIL COUNT; FEMALE; HEADACHE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LABORATORY TEST; MALE; MONOTHERAPY; NAUSEA; NORMAL HUMAN; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; BENZIMIDAZOLES; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; KETOCONAZOLE; MIDDLE AGED; RIBONUCLEOSIDES;

EID: 42949124357     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00951-07     Document Type: Article

References (16)

1. Biron, K. K., R. J. Harvey, S. C. Chamberlain, S. S. Good, A. A. Smith III, M. G. Davis, C. L. Talarico, W. H. Miller, R. Ferris, R. E. Dornsife, S. C. Stanat, J. C. Drach, L. B. Townsend, and G. W. Koszalka. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:2365-2372.
2. Drew, W. L., R. C. Miner, G. I. Marousek, and S. Chou. 2006. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J. Clin. Virol. 37:124-127.
3. Evers, D. L., G. Komazin, R. G. Ptak, D. Shin, B. T. Emmer, L. B. Townsend, and J. C. Drach. 2004. Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob. Agents Chemother. 48:3918-3927.
4. Huang, Y. C., J. L. Colaizzi, R. H. Bierman, R. Woestenborghs, and J. Heykants. 1986. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob. Agents Chemother. 30:206-210.
5. Kern, E. R., C. B. Hartline, R. J. Rybak, J. C. Drach, L. B. Townsend, K. K. Biron, and D. J. Bidanset. 2004. Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections. Antimicrob. Agents Chemother. 48:1749-1755.
6. Koszalka, G. W., N. W. Johnson, S. S. Good, L. Boyd, S. C. Chamberlain, L. B. Townsend, J. C. Drach, and K. K. Biron. 2002. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 46:2373-2380.
7. Krosky, P. M., M. C. Baek, and D. M. Coen. 2003. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 77:905-914.
8. Krosky, P. M., M. C. Baek, W. J. Jahng, I. Barrera, R. J. Harvey, K. K. Biron, D. M. Coen, and P. B. Sethna. 2003. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J. Virol. 77: 7720-7727.
9. Lalezari, J. P., J. A. Aberg, L. H. Wang, M. B. Wire, R. Miner, W. Snowden, C. L. Talarico, S. Shaw, M. A. Jacobson, and W. L. Drew. 2002. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46:2969-2976.
10. Lu, H., and S. Thomas. 2004. Maribavir (ViroPharma). Curr. Opin. Investig. Drugs 5:898-906.
11. Ma, J. D., A. N. Nafziger, S. A. Villano, A. Gaedigk, and J. S. Bertino, Jr. 2006. Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob. Agents Chemother. 50:1130-1135.
12. Ogu, C. C., and J. L. Maxa. 2000. Drug interactions due to cytochrome P450. Baylor Univ. Med. Cent. Proc. 13:421-423.
13. Olkkola, K. T., J. T. Backman, and P. J. Neuvonen. 1994. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55:481-485.
14. Swan, S. K., W. B. Smith, T. C. Marbury, M. Schumacher, C. Dougherty, B. A. Mico, and S. A. Villano. 2007. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. J. Clin. Pharmacol. 47:209-217.
15. Wang, L. H., R. W. Peck, Y. Yin, J. Allanson, R. Wiggs, and M. B. Wire. 2003. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 47:1334-1342.
16. Winston, D., J. van Burik, V. Pullarkat, G. Pananicolaou, R. Vij, E. Vance, G. Alangaden, R. Chemaly, F. Petersen, N. Chao, J. Klein, K. Sprague, C. Dougherty, S. Villano, and M. Boeckh. 2006. Prophylaxis against cytomegalovirus infections with oral maribavir in allogeneic stem cell transplant recipients: results of a randomized, double-blind, placebo-controlled trial. Blood 108:Abstract 593.